ReviewInternational journal of molecular sciences2022
Insights into Carbapenem Resistance in
Review in International journal of molecular sciences, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 12 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
12 citing papers in PubMed.
- Genomic and epidemiological insights into a non-toxigenic Vibrio cholerae O1 Ogawa from an autochthonous case in Brazil.European journal of clinical microbiology & infectious diseases : official publication of the European Society of Clinical Microbiology · 2026Article
- Multidrug-Resistant Vibrio spp. carrying carbapenemase genes in aquacultured shrimp and their zoonotic importance.Scientific reports · 2026Article
- Serotype and antimicrobial susceptibility patterns of Vibrio cholerae in cholera outbreak areas of East and Central Oromia Region, Ethiopia, 2024.BMC infectious diseases · 2026Article
- Unveiling the Modes of Action of a Recombinant Antimicrobial Peptide, Hepcidin (rGf-Hep), from Gerres filamentosus Against Pathogenic Vibrios: Membrane Disintegration and Reactive Oxygen Species Generation Leading to Cell Death.Probiotics and antimicrobial proteins · 2026Article
- Genomic portrayal of emerging carbapenem-resistant El Tor variantAntimicrobial agents and chemotherapy · 2025Article
- Genomic diversity and antimicrobial resistance ofMicrobial genomics · 2025Article
- Genetic basis of transmission of blaApplied microbiology and biotechnology · 2025Article
- Fatal seafood-borne carbapenem-resistant Vibrio cholerae peritonitis in a PD patient: lessons for the clinical nephrologist.Journal of nephrology · 2025Article
- Ultrasound combined with FeSOUltrasonics sonochemistry · 2024Article
- Duckweeds as edible vaccines in the animal farming industry.3 Biotech · 2024Review
- Public health aspects ofEFSA journal. European Food Safety Authority · 2024Article
- Vibrio cholerae O1 and Escherichia coli O157:H7 from drinking water and wastewater in Addis Ababa, Ethiopia.BMC microbiology · 2024Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
Abstract
The increasing prevalence of resistance in carbapenems is an escalating concern as carbapenems are reserved as last-line antibiotics. Although indiscriminate antibiotic usage is considered the primary cause for resistance development, increasing evidence revealed that inconsequential strains without any direct clinical relevance to carbapenem usage are harboring carbapenemase genes. This phenomenon indirectly implies that environmental microbial populations could be the 'hidden vectors' propelling carbapenem resistance. This work aims to explore the carbapenem-resistance profile of
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.